GCP
CRBP icon

GSA Capital Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

GSA Capital Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,056
Closed -$90K – 1799
2025
Q4 		$90K Buy
+11,056
New +$136K 0.01% 1541
2025
Q1 		– Sell
-36,647
Closed -$432K – 1722
2024
Q4 		$432K Buy
+36,647
New +$615K 0.03% 992
2022
Q2 		– Sell
-17,260
Closed -$275K – 1446
2022
Q1 		$275K Buy
+17,260
New +$229K 0.04% 956
2020
Q1 		– Sell
-1,916
Closed -$314K – 1133
2019
Q4 		$314K Buy
1,916
+1,391
+265% +$206K 0.04% 989
2019
Q3 		$77K Buy
+525
New +$91.4K 0.01% 1297
2018
Q4 		– Sell
-570
Closed -$129K – 1400
2018
Q3 		$129K Sell
570
-4,080
-88% -$660K 0.01% 1534
2018
Q2 		$704K Buy
+4,650
New +$845K 0.03% 960
2018
Q1 		– Sell
-2,217
Closed -$472K – 1635
2017
Q4 		$472K Sell
2,217
-1,143
-34% -$245K 0.03% 967
2017
Q3 		$721K Buy
3,360
+1,400
+71% +$274K 0.05% 726
2017
Q2 		$370K Buy
+1,960
New +$384K 0.02% 1155

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GSA Capital Partners's CRBP Position: Q1 2026 in Review

GSA Capital Partners sold out of Corbus Pharmaceuticals (CRBP) in Q1 2026, closing a stake of 11,056 shares — an estimated $90K sold.

GSA Capital Partners first reported a position in CRBP in Q2 2017 and held it in 10 quarters. The position peaked at $721K in Q3 2017. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • GSA Capital Partners reported no remaining Corbus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 11,056 Corbus Pharmaceuticals shares in Q1 2026, an estimated $90K.
  • GSA Capital Partners first reported a position in Corbus Pharmaceuticals in Q2 2017 and held it in 10 quarters.
  • GSA Capital Partners's Corbus Pharmaceuticals position peaked at $721K in Q3 2017.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.